SCHEMBL16670304

SCHEMBL16670304

COc1ccc(N(C)C(=O)C(Cc2cc(F)cc(F)c2)NC(=O)NS(=O)(=O)c2ccccc2F)cc1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.42
GAA P10253 1/20 0.42
BMP1 P13497 3/20 0.39
FPR2 P25090 1/20 0.38
KAT6A Q92794 5/20 0.37
KMT2A Q03164 2/20 0.37
CHRNB2 P17787 1/20 0.36
CHRNB4 P30926 1/20 0.36
CHRNA3 P32297 1/20 0.36
CHRNA4 P43681 1/20 0.36
BACE1 P56817 1/20 0.36
CYP3A4 P08684 1/20 0.35
CYP2C19 P33261 1/20 0.35
ALB P02768 1/20 0.35
IL2 P60568 1/20 0.35
PYGL P06737 1/20 0.35
MAPT P10636 1/20 0.35
BCHE P06276 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16670303 1.00 ALDH1A1 (0.42) ALDH1A1GAABMP1FPR2KAT6A
SCHEMBL16670286 0.92 MMP1 (0.38) ALDH1A1BMP1FPR2KMT2ABACE1
SCHEMBL16670289 0.92 MMP1 (0.38) ALDH1A1BMP1FPR2KMT2ABACE1
SCHEMBL18180124 0.84 BMP1 (0.40) BMP1FPR2KMT2ABACE1
SCHEMBL19969119 0.84 FPR2 (0.44) ALDH1A1BMP1FPR2KMT2ACYP3A4
SCHEMBL18180105 0.84 FPR2 (0.44) ALDH1A1BMP1FPR2KMT2ACYP3A4
SCHEMBL18180117 0.84 FPR2 (0.44) ALDH1A1BMP1FPR2KMT2ACYP3A4
SCHEMBL16671789 0.83 MAPT (0.32) ALDH1A1KAT6AKMT2APYGLMAPT
SCHEMBL18057233 0.83 PYGL (0.35) ALDH1A1KAT6AKMT2APYGLMAPT
SCHEMBL16671787 0.83 MAPT (0.32) ALDH1A1KAT6AKMT2APYGLMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10035760-B2 Inhibitors of human immunodeficiency virus replication VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2018-07-31 US disclosed
US-20160257645-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2016-09-08 US disclosed
EP-3060554-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION Bristol-Myers Squibb Company (US) 2016-08-31 EP disclosed
WO-2015061518-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY (US) 2015-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160257645-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION EIF2AK2, POLR1E, POLR1G ALDH1A1 3247/4885GAA 294/4885BMP1 4384/4885
US-10035760-B2 Inhibitors of human immunodeficiency virus replication EIF2AK2, POLR1G, POLR1E ALDH1A1 3035/4885GAA 272/4885BMP1 4383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.